

authorized to deduct said fees from Fulbright & Jaworski Deposit Account No. 50-1212/ARCD:347US.

I. AMENDMENT

In the Claims:

Please cancel claims 23-29 and 39-50, without prejudice or disclaimer.

Please add new claim 51 by amendment:

A --51. (New) The method of claim 4, wherein the active compound further comprises a non-ginsenoside component.--

II. RESPONSE

Claims 1-50 were pending at the time of the restriction requirement. In response to the restriction requirement which the Examiner imposed, Applicants elect, without traverse, to prosecute the Group I invention, as exemplified by claims 1-22 and 30-38, drawn to a method to treat diabetes or hyperglycemia, classified under Class 424, subclass 725. Accordingly, claims drawn to the Group II invention (claims 23-26), the Group III invention (claims 27-29), the Group IV invention (claims 39-41), and the Group V invention (claims 42-50) have been canceled from the present case without prejudice or disclaimer in the amendment contained herein.

Further, new claim 51 has been added by amendment. Support for claim 51 is found in the original claims and specification, and is within the elected Group I invention.

In view of the above, claims 1-22, 30-38, and 51 are pending in the case. A copy of the claims as pending is found in Appendix A.

In response to the species election requirement entered by the Examiner in the event that Applicants elect the Group I claims, Applicants elect the route of administration as alimentary